Dr Reddy's COO On US Derma Build-Up, One-Sided Biologics Norms
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories (DRL) appears to be building on plans for its differentiated dermatology and neurology formulations in the US after gains on the approvals front.
You may also be interested in...
Psoriasis Sprays: Niche Opportunities?
Expanding treatment options for psoriasis highlight how some firms are developing innovative "lower risk" assets that use established active ingredients but could provide benefits to specific patient segments.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet